Galapagos NV (Galapagos NV) Days Inventory : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Galapagos NV's Average Total Inventories for the three months ended in Dec. 2023 was $70.0 Mil. Galapagos NV's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.0 Mil.

The historical rank and industry rank for Galapagos NV's Days Inventory or its related term are showing as below:

GLPG' s Days Inventory Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1526.56
Current: 1526.56

During the past 13 years, Galapagos NV's highest Days Inventory was 1526.56. The lowest was 0.00. And the median was 0.00.

GLPG's Days Inventory is ranked worse than
93.68% of 649 companies
in the Biotechnology industry
Industry Median: 191.36 vs GLPG: 1526.56

Galapagos NV's Days Inventory stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Warning Sign:

If a company builds up inventory, it may mean it is having difficulties selling its goods.

Inventory Turnover measures how fast the company turns over its inventory within a year. Galapagos NV's Inventory Turnover for the three months ended in Dec. 2023 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Galapagos NV Days Inventory Historical Data

The historical data trend for Galapagos NV's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Days Inventory Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Inventory	Get a 7-Day Free Trial															-	1,330.25	1,069.32	842.21	-

Competitive Comparison of Galapagos NV's Days Inventory

For the Biotechnology subindustry, Galapagos NV's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Days Inventory distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Days Inventory falls into.

Galapagos NV Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Galapagos NV's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (56.065	+	80.674)	/	2 )	/	0	*	365
=	68.3695					/	0	*	365
=	N/A

Galapagos NV's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (59.344	+	80.674)	/	2 )	/	0	*	365 / 4
=	70.009					/	0	*	365 / 4
=	N/A

Galapagos NV (NAS:GLPG) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Galapagos NV's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	70.009
	=	0.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Galapagos NV's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	70.009	/	-228.052
	=

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Galapagos NV Days Inventory Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.